Evidence map›Paper›PMID 40264583›Full record

ArticleActa naturae

Inhibition of HBV Replication by a Fully Humanized Neutralizing Antibody In Vivo and In Vitro.

Zhipeng Zhang, Yanqin Ma, Yan He, Dong Wang, Huaien Song, Kun Yue, Xiaomei Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta naturae. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhipeng ZhangLaboratory of Pharmaceutical Engineering, School of Life Science and Health Engineering, Jiangnan University, Wuxi, 214122 China.
Yanqin MaSuzhou Hepa Thera Biopharmaceutical Co., Ltd., Shanghai, 200120 China.
Yan HeSuzhou Hepa Thera Biopharmaceutical Co., Ltd., Shanghai, 200120 China.
Dong WangSuzhou Hepa Thera Biopharmaceutical Co., Ltd., Shanghai, 200120 China.
Huaien SongSuzhou Hepa Thera Biopharmaceutical Co., Ltd., Shanghai, 200120 China.
Kun YueSuzhou Hepa Thera Biopharmaceutical Co., Ltd., Shanghai, 200120 China.
Xiaomei ZhangLaboratory of Pharmaceutical Engineering, School of Life Science and Health Engineering, Jiangnan University, Wuxi, 214122 China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neutralizing antibodies are capable of specifically binding to the HBsAg virus, thereby preventing HBV infection and subsequently reducing viral antigen load in both the liver and systemic circulation. This has significant implications for restoring the postnatal immune function. By utilizing the phage antibody library technology, we successfully screened a fully humanized neutralizing antibody targeting the hepatitis B surface antigen. The antiviral activity was assessed in primary human hepatocytes (PHHs) by determining the EC

Indexed as

CDC effectHBsAgNeutralizing antibody

Identifiers

PMID40264583
PMCPMC12011186

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.